The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.
Giacomo Giulio BaldiMehdi BrahmiSalvatore Lo VulloElena CojocaruOlivier MirMichela CasanovaBruno VincenziTommaso Martino De PasGiovanni GrignaniMaria Abbondanza PantaleoJean Yves BlayRobin Lewis JonesAxel Le CesneAnna Maria FrezzaAlessandro GronchiPaola ColliniAngelo Paolo Dei TosCarlo MorosiLuigi MarianiPaolo Giovanni CasaliSilvia StacchiottiPublished in: The oncologist (2020)
Inflammatory myofibroblastic tumor (IMT) is an ultrarare sarcoma with known sensitivity to anaplastic lymphoma kinase (ALK) inhibitors in ALK-fused cases, although ALK inhibitors are not licensed in the disease. The current knowledge on the activity of cytotoxic chemotherapy is limited. This multi-institutional retrospective study on pediatric and adult patients with IMT shows that cytotoxic chemotherapy, and in particular anthracycline-based and methotrexate plus/minus vinorelbine/vinblastine regimens, represents a treatment option and can be considered in IMT patients irrespectively from ALK status. This study provides a benchmark for future studies on new medical therapies.
Keyphrases
- advanced non small cell lung cancer
- locally advanced
- end stage renal disease
- healthcare
- ejection fraction
- oxidative stress
- newly diagnosed
- chronic kidney disease
- cross sectional
- prognostic factors
- diffuse large b cell lymphoma
- clinical trial
- rectal cancer
- phase ii study
- tyrosine kinase
- epidermal growth factor receptor
- replacement therapy
- low dose
- protein kinase
- study protocol
- anti inflammatory